Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.55), $0.08 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $3.31 million versus the consensus estimate of $3.56 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.